H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions
Saturday, November 18, 2023, 12:45 PM – 1:45 PM
This Sponsored Satellite Symposium will discuss the current diagnosis, treatment strategies, and clinical trials for H3 K27M-mutant diffuse glioma.
The H3 K27M mutation frequently occurs in diffuse midline glioma (DMG) and confers an inferior prognosis with an overall survival of only one year. While most commonly found in DMG, the H3 K27M mutation is occasionally identified in hemispheric glioma as well. Radiation is thought to confer only transient benefit and there are currently no approved systemic therapies specifically for this disease. H3 K27M-mutant glioma is associated with unmethylated MGMT-promoter status, which has been associated with high grade glioma resistance to temozolomide. Together, these factors underscore the urgency of unmet need for novel, effective therapeutics for H3 K27M-mutant diffuse glioma.